- Home
- ESTC vs BBIO Comparison
ESTC vs BBIO Comparison
Compare ESTC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTC
- BBIO
- Stock Information
- Founded
- ESTC 2012
- BBIO 2015
- Country
- ESTC Netherlands
- BBIO United States
- Employees
- ESTC N/A
- BBIO N/A
- Industry
- ESTC Computer Software: Prepackaged Software
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ESTC Technology
- BBIO Health Care
- Exchange
- ESTC Nasdaq
- BBIO Nasdaq
- Market Cap
- ESTC 9.4B
- BBIO 9.4B
- IPO Year
- ESTC 2018
- BBIO 2019
- Fundamental
- Price
- ESTC $86.72
- BBIO $53.38
- Analyst Decision
- ESTC Buy
- BBIO Strong Buy
- Analyst Count
- ESTC 27
- BBIO 16
- Target Price
- ESTC $120.75
- BBIO $63.81
- AVG Volume (30 Days)
- ESTC 2.4M
- BBIO 2.3M
- Earning Date
- ESTC 08-28-2025
- BBIO 08-05-2025
- Dividend Yield
- ESTC N/A
- BBIO N/A
- EPS Growth
- ESTC N/A
- BBIO N/A
- EPS
- ESTC N/A
- BBIO N/A
- Revenue
- ESTC $1,551,164,000.00
- BBIO $235,812,000.00
- Revenue This Year
- ESTC $14.61
- BBIO $115.49
- Revenue Next Year
- ESTC $12.53
- BBIO $64.61
- P/E Ratio
- ESTC N/A
- BBIO N/A
- Revenue Growth
- ESTC 17.43
- BBIO 7.62
- 52 Week Low
- ESTC $69.00
- BBIO $21.72
- 52 Week High
- ESTC $118.84
- BBIO $53.97
- Technical
- Relative Strength Index (RSI)
- ESTC 59.96
- BBIO 63.37
- Support Level
- ESTC $83.11
- BBIO $49.75
- Resistance Level
- ESTC $86.34
- BBIO $52.85
- Average True Range (ATR)
- ESTC 3.10
- BBIO 2.12
- MACD
- ESTC 1.10
- BBIO 0.18
- Stochastic Oscillator
- ESTC 59.24
- BBIO 91.76
About ESTC Elastic N.V.
Elastic is a software company based in Mountain View, California, focusing on search-adjacent products. Its search engine allows it to process both structured and unstructured data while gleaning insights from that data. The firm's primary focus is on enterprise search, observability, and security.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.